🔥 We are so excited to share with you that NeuroClues™ is amongst the very few promising start-ups (<8%) awarded the prestigious EIC accelerator funding! We are now ready to move to the next phase: demonstrating the clinical use of neuroClues in the diagnosis of Parkinson’s Disease and supporting its early commercial roll-out! 🇪🇺 The European Innovation Council (EIC) is the EU Commission's flagship innovation program to identify, develop and scale up breakthrough technologies and game-changing innovations. The EIC Accelerator provides substantial financial support with grant funding and direct equity investments managed by the EIC Fund. 🚀 This recognition confirms our ambition for NeuroClues™ to become the brain’s stethoscope, supporting 10M patients by 2030. Congratulations to the whole team! We’re on the right track to fulfill our mission, with the support from Institut du Cerveau – Paris Brain Institute and iPEPS The Healthtech Hub. More info on the press release: https://lnkd.in/g5pZPmAH European Innovation Council and SMEs Executive Agency (EISMEA) invest.bw Graph Ventures Pierre de Waha L'Echo Antoine Pouppez Pierre Daye Pierre Pouget Jean-Baptiste de Harenne Marie Dautrebande Camille Verriest Frédérique Boël Florian Guyot Mark Turcksin Alejandra Mejia Philippe Domineaux Valérie Roels Caroline Van den Eynde @Tym Poitou Bao Nguyen Simon Gerard #EUeic #eicAccelerator #neuroscience #innovationinhealthcare #capitalventure #funding #scaling
neuroClues
Medical Equipment Manufacturing
Louvain-la-Neuve, Walloon Region 3,958 followers
Biomarkers in a Blink
About us
In a world where Neurological disorders will affect 1 person in 3 and where the number of parkinson's patient will double in the next decade, reaching 13 million patients. Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms. Our ambition with NeuroClues is to become the brain's stethoscope. We are a team of seasoned MedTech entrepreneurs and doctors with as purpose to help our healthcare system cross the chasm of technology with pragmatic solutions. We work from anywhere but our base camps are in Louvain-la-Neuve, Belgium & Paris, France & NY, USA. We’re are looking to connect with individuals, companies, investors and Key Opinion Leaders that share our ambition and mission and that would be willing to partner with us in order to bring NeuroClues to the EU and US market.
- Website
-
http://www.neuroclues.com
External link for neuroClues
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Louvain-la-Neuve, Walloon Region
- Type
- Privately Held
- Founded
- 2020
- Specialties
- neurosciences, parkinson, eyetracking, and Neurology
Locations
-
Primary
1, Avenue Jean Monnet
Louvain-la-Neuve, Walloon Region 1348, BE
-
187 Rue Chevaleret
c/o IPEPS @ICM
Paris, 75013, FR
Employees at neuroClues
-
Pierre de Waha
Senior Investment Manager at Invest.BW: Private Equity | Venture Capital | Innovation | Fund Raising | Investment
-
Heather Keith
U.S. Head of Sales
-
Jean-Baptiste de Harenne
Empowering practitioners with a window to brain health
-
Pierre Daye
Coaching the Technical side of an Organisation, Founder at P³Lab, Substitute Professor in Neuroscience
Updates
-
🧠 Today is #WorldMSADay, a crucial time to raise awareness about a disease with a misdiagnosis rate as high as 20%. ⚕️ Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder affecting the central and autonomic nervous systems. It causes movement difficulties, balance and coordination issues, and autonomic dysfunction. The disease progresses rapidly, leading to increased disability and often necessitating walking aids. 👁️ A crucial aspect of #MSA is eye movement dysfunction, caused by degeneration in brainstem structures that control eye movements. Diagnosing MSA is particularly challenging: 🩺 MSA is categorized as an atypical parkinsonian syndrome due to its resemblance to Parkinson's disease. It’s frequently misdiagnosed as Parkinson's or progressive supranuclear palsy, complicating research efforts across all three conditions. 🩺MSA presents in two distinct forms: MSA-P (parkinsonian type) and MSA-C (cerebellar type), each with unique clinical features, progression rates, and treatment responses. These 2 forms are hard to distinguish. New research highlights the potential of eye movement monitoring to revolutionize MSA diagnosis and care. It offers the ability to: 🔬Improve diagnostic accuracy, reducing the need for unnecessary invasive tests 🔬Enhance patient selection for clinical trials, ultimately speeding up the development of new treatments 💪Today, let's raise awareness and work towards better outcomes for those living with MSA. Bas Bloem Marcel Verbeek Bart van de Warrenburg Multiple System Atrophy Trust Mission MSA International Parkinson and Movement Disorder Society National Organization for Rare Disorders #biomarkers #neuroscience #eyetracking
The purpose of World MSA Day is to raise awareness about multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder that affects the body's autonomic functions. Join us in acknowledging the strength of those impacted by MSA. Our Path to a Cure 5K fundraising event series is our way of spreading awareness, raising crucial funds, and bringing the community together to drive progress towards a future without this rare disease. Thank you to those who have donated or are taking part in our events, whether you joined us in Dallas last weekend, our Chicago 5K this Sunday, or our virtual 5K that kicks off today! Your involvement helps us make an impact! To make a contribution, click here: https://lnkd.in/gazd5Xbu #WorldMSADay #MSA #multiplesystematrophy #MissionMSA #donation #donate #raredisease #rarediseaseawareness #msaawareness #PathtoaCure5K #PathtoaCure #Dallas #Chicago #Virtual #5K #fundraiser #fundraising #getinvolved #contribute
-
🎯 Rencontrez Tymothée Poitou, notre conseiller clinique, à la SOFMER du 2 au 4 octobre ! La Société Française de Médecine Physique et de Réadaptation (#SOFMER) est le rendez-vous incontournable pour découvrir les dernières avancées en rééducation et médecine physique. 💡 Tymothée Poitou y présentera "Vers une nouvelle évaluation quantifiée de l’hémiparésie aiguë post-AVC : le score early Composite XA", un outil qui permet de mesurer et suivre la faiblesse musculaire post-AVC, améliorant ainsi la rééducation des patients. 👀 Mais ce n’est pas tout ! Tymothée partage également notre intérêt pour les mouvements oculaires, essentiels dans le diagnostic et le suivi des maladies neurologiques. N’hésitez pas à le solliciter si ce sujet vous passionne – il sera ravi d’en discuter avec vous ! #biomarkers #neuroscience #eyetracking #SOFMER24
-
🏎️ We’re not slowing down! Next stop: Chicago, for the Society for Neuroscience's annual meeting. 🧠Neuroscience is where it all began for our co-founders, Pierre Daye and Pierre Pouget. Their dedication to the field sparked years of research, particularly focusing on eye movements—a passion that became the foundation of our work. 🤝This event is meaningful for us, as we’re connecting with fellow neuroscientists who recognize the potential of eye movements research. 💪 We’re back with another poster on Sunday, October 6th! Don’t miss ‘Pupillometry and Geometrical Characteristics Parameters during Visual and Oculomotor Tasks’ by our co-founders Pierre Daye and Pierre Pouget. It explores the latest research and the exciting opportunities for innovation in developing more advanced pupillometry metrics. 🙌Swing by booth #158, where we'll showcase our efforts to bring the wealth of eye tracking research to the clinical practice. Our goal? Offer a device which allows this translation from research to clinic through a simple workflow and uncompromised technical capabilities. #neuroscience #biomarkers #eyetracking * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.
-
💜 On September 21st, we recognized World Alzheimer’s Day—a vital occasion to raise awareness and share experiences related to this challenging condition. It’s a time to reflect on the lives of those affected by Alzheimer’s and to honor the dedication of healthcare practitioners who tirelessly support patients and their families. 🥼 We also acknowledge the researchers who are passionately working to uncover effective treatments for this complex disease. The prevalence of all-cause dementia is projected to rise from 50 million in 2010 to an alarming 153 million by 2050 worldwide. As a company dedicated to medical innovation, we recognize the growing challenge that Alzheimer’s presents and are inspired to take action. ✨At neuroClues, we are dedicated to making a meaningful impact. Our goal is to empower neurologists, enabling them to make informed decisions that lead to earlier and more accurate diagnoses for patients. Together, let’s work towards improving the journey for those affected by Alzheimer’s. Alzheimer's Society Alzheimer's Association® Alzheimer's Foundation of America Alzheimer's Disease International Alzheimer's Drug Discovery Foundation American Brain Foundation BrightFocus Foundation Alzheimer's Research UK #biomarkers #eyetracking #neuroscience #EndAlz #AlzheimersAwareness #GoPurple * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.
-
🧳 We’re gearing up for the 2024 International Parkinson and Movement Disorder Society meeting! 🥼This event brings together clinicians, researchers, and industry leaders to advance the treatment of movement disorders and support those affected by Parkinson’s and similar conditions. How could eye-tracking benefit those with Parkinson’s and other movement disorders? 🔍Early detection: Eye movement abnormalities often emerge before clinical symptoms, and having the right tool to detect these early changes could provide clues to faster diagnosis and treatment. 🩺Accurate diagnosis: Eye movement analysis could help distinguish Parkinson’s from other movement disorders, preventing misdiagnosis and unnecessary treatments that could worsen the condition. 📝Treatment monitoring: By tracking eye movement improvements, practitioners could assess treatment effectiveness over time. 👀 Don't miss Pierre Daye’s poster presentation on Saturday, Sept 28th, presenting promising preliminary evidence for a potential pre-clinical Parkinson's test based on eye movements. While more studies are needed to confirm these findings, we're excited to share this breakthrough ! 👩🏫Our team of experts is ready to show you how the right tool for quantifying eye movements can be a game-changer in your consultations. Swing by booth #217 and discover the potential of eye movement analysis firsthand! #biomarkers #eyetracking #neuroscience #MDS #MDS24 #MDSCongress * neuroClues is in research & development phase and its commercial availability is pending regulatory approval.
-
🌟We’re Heading to Athens for# ESSEM24! 📚The @European Summer School on Eye Movements (#ESSEM) is an educational event that explores eye movement research, bringing together researchers and students from various fields. ESSEM provides opportunities for networking and learning from leading experts, offering insights into current research methodologies and findings. 🎤Our own Pierre Pouget, co-founder and scientific advisor, will be leading multiple presentations. He'll kick off with an introduction to eye movements, explore animal studies in neuroscience, and conclude with an update on our innovative project, neuroClues—neurologist’s future companion. 🔬Eye movements have been linked to neurological disorders, and having the right tools can transform early diagnosis, treatment, and follow-up. Events like #ESSEM are vital for showcasing the critical role of eye tracking in neurology and the need for advanced diagnostic tools. They hold a special place in our hearts as they help raise awareness about the power of eye tracking. 👁️The eyes reveal so much, let’s take advantage of that. 🤝If you can’t make it to Athens but want to learn more about eye movements, let’s connect! We’d love to discuss. Nikolaos Smyrnis, Chrystalina Antoniades, Giuseppe Boccignone, Olaf Dimigen, Johanna Kaakinen, Kristof Keidel, Päivi Majaranta, Susana Martinez-Conde, Dr. Rima-Maria Rahal #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and will soon go through regulatory approval.
-
🔍 New Horizons in #MS Research with Eye Tracking Technology 🧠 Multiple Sclerosis is a chronic inflammatory neurological disorder affecting approximately 2.8 million people worldwide. It can cause a range of symptoms, including coordination and balance issues, movement disorders, and vision and cognitive impairments. 👀 Since MS can impact various parts of the central nervous system, it’s no surprise that eye movement disorders are commonly observed in MS patients. Given that eye movement circuits encompass multiple brain regions, analyzing eye movements can provide valuable insights into the disease. Here are two recent studies highlighted in our August newsletter: 📄 Suh et al. (2024) reveal how eye-tracking technology can serve as a non-invasive tool to objectively measure saccadic disorders, aiding in early diagnosis, disease monitoring, and treatment evaluation. 📄Nij Bijvank et al. (2023) demonstrate that the double-step saccadic test is a promising alternative for assessing treatment efficacy, compared to traditional single saccadic tests. 🤿 Dive into our full article to see how these innovations could revolutionize MS care. 📩Curious to stay up to date with the latest advancements in eye tracking and MS research? Sign up for our monthly newsletter to get the latest insights and updates delivered straight to your inbox (link in the comments) Sam Hof, Menno Schoonheim,Alex Suh, Gilad Hampel, Aditya Vinjamuri, Nasif Zaman, Alireza Tavakkoli Andrew Lee MS Canada MSPLUS FOUNDATION EMSP - European Multiple Sclerosis Platform MS Society National MS Society Multiple Sclerosis Foundation Multiple Sclerosis Association of America (MSAA) Multiple Sclerosis Ireland #biomarkers #eyetracking #neuroscience * neuroClues is in research & development phase and will soon go through regulatory approval.
Clinical highlights: Multiple Sclerosis (MS) - neuroClues
https://neuroclues.com
-
💔 Detecting heart failures through the pupils 🏥 Heart failure (HF) is the primary reason for hospital admissions among people over 65, comprising 1-2% of hospitalizations in Western nations. With over 60 million affected worldwide, HF significantly impacts healthcare costs and patient quality of life on a global scale. 🫀#HF occurs when the heart cannot generate sufficient cardiac output to meet the body's metabolic demands. This condition triggers neurohormonal responses, including the activation of the sympathetic nervous system (#SNS) and the subsequent release of adrenaline and noradrenaline. These hormones interact with adrenergic receptors in the iris, leading to pupillary dilation. 👀 In their study, Zamorano et al. (2024) explore the potential of pupillometry as a tool and discover that patients with decompensated heart failure exhibit larger baseline pupil diameters and faster pupil dilation velocities compared to healthy controls, indicating SNS hyperactivation. 🩺These findings suggest that pupillometry offers a non-invasive, simple, and cost-effective method for assessing SNS activity and predicting prognosis in HF patients, thereby improving patient care and management. #biomarkers #neuroscience #eyetracking @Margarita Zamorano, @Juan Manuel Monteagudo, @Eduardo González , @Isabel Rayo, Sara Fra Fernández , @Miguel Castillo, @Qiheng Zhou, @Pedro de la Villa, @Jose Luis Zamorano Hospital Ramón y Cajal Hospital Universitario Ramón y Cajal Universidad de Alcalá European Society of Cardiology Heart Failure Society of America American Heart Association British Society for Heart Failure Canadian Heart Failure Society * These statements are not neuroClues product-specific claims but scientifically backed evidence of the clinical relevance of eye tracking
Pupil reflex as a marker of activity and prognosis in heart failure: a longitudinal and prospective study - PubMed
pubmed.ncbi.nlm.nih.gov
-
“I think that we highlighted the clinical value of ocular motor dysfunction in corticobasal syndrome (#CBS)” stated Jacy Parmera on the International Parkinson and Movement Disorder Society podcast 🍀 CBS is a rare neurological condition affecting about 5 in 100,000 people. It typically begins with movement difficulties on one side of the body, such as stiffness or impaired control of an arm or leg. As it progresses, symptoms can spread to both sides and include cognitive and behavioural changes. 🔍CBS can arise from conditions like corticobasal degeneration (#CBD), Alzheimer’s disease (#AD), and progressive supranuclear palsy (#PSP), which have overlapping symptoms that make differentiation challenging. 🩺 Identifying abnormal eye movement patterns in CBS could serve as a crucial clinical indicator. These ocular motor dysfunctions might help pinpoint the underlying cause of CBS, particularly for 4-R tauopathies such as corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP) Why is understanding the underlying condition crucial? ❓Treatment: Treatment for CBS varies with the underlying pathology; incorrect treatment can result in poor outcomes and missed opportunities for personalized care. ❓Prognosis: Accurate identification of the underlying condition allows healthcare providers to offer better prognostic information, aiding in future care planning. 🚀At neuroClues, we are dedicated to developing the neurologist’s companion: a tool that empowers them in providing a better diagnosis and improved follow-up of neurological conditions. Michele Matarazzo, Isabel Junqueira de Almeida, Marcos Castello Barbosa de Oliveira , Carlos Buchpiguel , Artur Martins N. Coutinho USP - Universidade de São Paulo #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and will soon go through regulatory approval.
Corticobasal syndrome (CBS) has diverse underlying pathologies, including 4-repeat tauopathies. Dr. Jacy Parmera shares the findings of her multimodal imaging study to distinguish the clinical features of CBS. https://loom.ly/YOO4um8